Research Article

Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study

Volume: 3 Number: 3 March 15, 2019
EN TR

Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study

Abstract

Aim: Irisin, which is proteolytically splited form of fibronectin type III domain containing 5 (FNDC5), is a protein with 112 amino acid. Irisin is an exercise-induced hormone excreted primarily by cardiac muscle and skeletal cells which can be described as an exercise hormone and a new potential target for the treatment of metabolic diseases and obesity. Our goal was to evaluate the serum irisin levels in patients with endometrial hyperplasia (EH). 

Methods: An observational study is planned. The study population consisted of two groups: 1) the EH group (study group), consisting of participants who had been histopathologically diagnosed with simple EH without atypia and 2) the control group, consisting of healthy participants admitted to the clinic for an annual examination without any complaints or symptoms. Primary outcome of the study was evaluation irisin status. Serum irisin levels were determined by an enzyme-linked immunosorbent assay (ELISA) method.

Results: After sample size analysis, 52 participants enrolled into the study as study group (EH group) (n=26) and control group (n=26). The mean age was 39.5±3.8 years in the EH group and 40.7±2.4 years in the control group (p=0.258). Mean BMI was 28.8±2.1 kg/m2 in the EH group and 28.5±1.2 kg/m2 in the control group (p=0.666). Gravidity, parity, systolic blood pleasure, diastolic blood pleasure, fasting glucose levels, smoking status, alcohol use were similar for both groups (p=0.499, p=0.278, p=0.248, p=0.424, p=0.646, p=0.486 and p=0.153, respectively). In control group regular exercise rates was significantly higher than EH group (26.9%, 3.84%, respectively p<0.001). The mean serum irisin level was 1.9±0.7 μg/ml in the EH group and 3.5±2.0 μg/ml in the control group. Serum irisin levels were found to be significantly lower in the EH group compared to the control group (p<0.001). 

Conclusion: The data from the current study indicate that serum irisin levels were significantly decreased in patients with endometrial hyperplasia. Serum irisin levels may open up new horizons for therapeutic targets for the treatment of patients with EH.

Keywords

References

  1. 1. Sahin E, Eraslan Sahin M, Dolanbay M, et al. Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins. Gynecol Endocrinol. 2018 May;34(5):433-6.
  2. 2. Daud S, Jalil SS, Griffin M, et al. Endometrial hyperplasia - the dilemma of management remains: a retrospective observational study of 280 women. Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):172-5. doi: 10.1016/j.ejogrb.2011.06.023. PubMed PMID: 21764501.
  3. 3. Beavis AL, Smith AJ, Fader AN. Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management. Int J Womens Health. 2016;8:151-67. doi: 10.2147/IJWH.S88367. PubMed PMID: 27284267; PubMed Central PMCID: PMCPMC4883806.
  4. 4. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004 Jan;84(1):277-359. doi: 10.1152/physrev.00015.2003. PubMed PMID: 14715917.
  5. 5. Gannon NP, Vaughan RA, Garcia-Smith R, et al. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer. 2015 Feb 15;136(4):E197-202. doi: 10.1002/ijc.29142. PubMed PMID: 25124080.
  6. 6. Provatopoulou X, Georgiou GP, Kalogera E, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015 Nov 11;15:898. doi: 10.1186/s12885-015-1898-1. PubMed PMID: 26560078; PubMed Central PMCID: PMCPMC4642638.
  7. 7. Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism. 2014 Feb;63(2):188-93. doi: 10.1016/j.metabol.2013.10.005. PubMed PMID: 24268368.
  8. 8. Blizzard LeBlanc DR, Rioux BV, Pelech C, et al. Exercise‐induced irisin release as a determinant of the metabolic response to exercise training in obese youth: the EXIT trial. Physiological reports. 2017;5(23).

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Publication Date

March 15, 2019

Submission Date

March 6, 2019

Acceptance Date

March 10, 2019

Published in Issue

Year 2019 Volume: 3 Number: 3

APA
Şahin, E., Eraslan Şahin, M., Madendağ, Y., Çöl Madendağ, İ., Tayyar, A. T., Gözüküçük, M., Karakükçü, C., & Açmaz, G. (2019). Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study. Journal of Surgery and Medicine, 3(3), 242-245. https://doi.org/10.28982/josam.536426
AMA
1.Şahin E, Eraslan Şahin M, Madendağ Y, et al. Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study. J Surg Med. 2019;3(3):242-245. doi:10.28982/josam.536426
Chicago
Şahin, Erdem, Mefküre Eraslan Şahin, Yusuf Madendağ, et al. 2019. “Evaluation of Serum Irisin Levels in Patients With Endometrial Hyperplasia: A Controlled Cross-Sectional Study”. Journal of Surgery and Medicine 3 (3): 242-45. https://doi.org/10.28982/josam.536426.
EndNote
Şahin E, Eraslan Şahin M, Madendağ Y, Çöl Madendağ İ, Tayyar AT, Gözüküçük M, Karakükçü C, Açmaz G (March 1, 2019) Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study. Journal of Surgery and Medicine 3 3 242–245.
IEEE
[1]E. Şahin et al., “Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study”, J Surg Med, vol. 3, no. 3, pp. 242–245, Mar. 2019, doi: 10.28982/josam.536426.
ISNAD
Şahin, Erdem - Eraslan Şahin, Mefküre - Madendağ, Yusuf - Çöl Madendağ, İlknur - Tayyar, Ahter Tanay - Gözüküçük, Murat - Karakükçü, Ciğdem - Açmaz, Gökhan. “Evaluation of Serum Irisin Levels in Patients With Endometrial Hyperplasia: A Controlled Cross-Sectional Study”. Journal of Surgery and Medicine 3/3 (March 1, 2019): 242-245. https://doi.org/10.28982/josam.536426.
JAMA
1.Şahin E, Eraslan Şahin M, Madendağ Y, Çöl Madendağ İ, Tayyar AT, Gözüküçük M, Karakükçü C, Açmaz G. Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study. J Surg Med. 2019;3:242–245.
MLA
Şahin, Erdem, et al. “Evaluation of Serum Irisin Levels in Patients With Endometrial Hyperplasia: A Controlled Cross-Sectional Study”. Journal of Surgery and Medicine, vol. 3, no. 3, Mar. 2019, pp. 242-5, doi:10.28982/josam.536426.
Vancouver
1.Erdem Şahin, Mefküre Eraslan Şahin, Yusuf Madendağ, İlknur Çöl Madendağ, Ahter Tanay Tayyar, Murat Gözüküçük, Ciğdem Karakükçü, Gökhan Açmaz. Evaluation of serum irisin levels in patients with endometrial hyperplasia: A controlled cross-sectional study. J Surg Med. 2019 Mar. 1;3(3):242-5. doi:10.28982/josam.536426